7th B2B Uro-Oncology: GU Cancers Triad Meeting - PROSTATE CANCER

Friday, October 31, 2025

14:40 - 16:20 GMT+0

Co-Chair(s)

Caroline Moore

NIHR Research Professor & Head of Urology
University College London, United Kingdom

B2B Scientific Programme Committee: Peter Black, Canada / Caroline Moore, United Kingdom / Simon Tanguay, Canada

At the end of this session, attendees should be able to:

Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer
Recognize the role of imaging and genetic markers in guiding treatment decision-making.
Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

14:40 - 15:10 GMT+0

Case-Based Panel Discussion: Focal therapy in localized prostate cancer – assessing different energy sources
Moderator: Caroline Moore – University College London
Panelist: Kara Watts – Albert Einstein College of Medicine
Panelist: Alistair Grey – UCLH
15:10 GMT+0

Robotic Prostatectomy Balloon Debate: The Data on X Approach Is Sufficient for Widespread Implementation
15:10 - 15:50 GMT+0

Hood
Debater: Alan McNeill – Scotland
15:10 - 15:50 GMT+0

NeuroSAFE
15:10 - 15:50 GMT+0

Retzius Sparing
15:10 - 15:50 GMT+0

Single Port
15:50 - 16:05 GMT+0

SOA: The role of metformin plus ADT in mHSPC – a STAMPEDE update
16:05 - 16:20 GMT+0

SOA: Theranostics in Locally Advanced Prostate Cancer